CorPath system to be featured for the first time in Japan


Augusto D Pichard, interventional cardiologist at Washington Hospital Center and professor of medicine at the George Washington University Medical Center, will discuss how robotic-assisted percutaneous coronary interventions (PCI) are applied in a modern cath lab during his presentation entitled “Robotic Coronary Angioplasty” at the 24th Annual Meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics: CVIT 2015 (July 30–1 August, Fukuoka City, Japan).

Japan is a large market for interventional cardiology with 250,000 PCIs performed annually across 1,000 hospitals, and has historically shown interest in robotics and radiation protection. Corindus has been invited by Takafumi Ueno, president of CVIT 2015, to present the CorPath system in the exhibit hall for hands-on demonstrations for attendees.

“While many devices have been introduced in Japan since the first coronary intervention was performed here more than 35 years ago, we had a limited number of innovations that offered both protection for physicians and potential to improve clinical outcomes,” said Ueno, professor of medicine, Cardiovascular Center, Kurume University Hospital. “The interventional cardiology community is open to new ideas and innovative technologies and we welcome the CorPath system to help us explore the advantages a robotic system can add to our practice.”

Corindus says that its CorPath system is the first Food and Drug Administration-cleared medical device to bring robotically-assisted precision to coronary angioplasty procedures in the USA. The CorPath system is used in cath labs throughout the USA for complex PCIs. In addition to allowing cardiologists to advance stents and guidewires with precision using digital controls, the system enables physicians to perform procedures while seated in a lead-lined interventional cockpit protected from radiation exposure.

“CorPath is already providing robotic precision during PCI procedures while protecting physicians from the serious occupational hazards in interventional cardiology here in the USA,” said David Handler, president and chief executive officer of Corindus. “Japan is an important market for interventional cardiology and it is an honour to be invited to participate in this year’s CVIT conference.”